Phase 1 Pharmacokinetic (PK) Assessment of ATI-1123, a Novel Human Serum Albumin-Stabilized Nanoparticle Docetaxel Liposomal Formulation, in Patients with Advanced Solid Malignancies

Purpose:

ATI-1123, a novel nanoparticle docetaxel liposomal formulation, is being investigated in patients (pts) with advanced solid malignancies.ATI-1123 is expected to reduce hypersensitivity reactions, have a broader therapeutic index and to enhance systemic exposure to docetaxel. The objective of this study was to investigate the safety, tolerability, pharmacokinetics and tumor response of ATI-1123 in pts with advanced solid tumors following escalating doses of intravenously administered ATI-1123.